Company: Sun Pharmaceutical Industries Ltd. Category: IPO Notes


Sun Pharmaceutical Industries (SPIL) is India’s largest and the world’s fifth-largest generic pharmaceutical company.
March 5, 2019, 2:21 p.m.
Publisher: nirmalbang.com

Net Sales are expected to increase by 14.4 percent Y-o-Y (up 9.7 percent Q-o-Q) to Rs. 7,609 crore, according to ICICI Direct.
Jan. 11, 2019, 6:09 p.m.
Publisher: moneycontrol.com

Net Revenues for the quarter increased by 4.3% YoY to Rs 69.4 bn, below our expectation of Rs 75.8 bn.
Nov. 14, 2018, 10:54 a.m.

Sun Pharmaceutical Industries (SUNP) has delivered a below par performance in Q2FY19.
Nov. 14, 2018, 10:50 a.m.
Publisher: trade.rsec.co.in


SUNP’s net sales, adj. EBITDA and adj. PAT declined by 4%, 5% and 1% QoQ respectively due to declining sales in negative development in key geographies.
Nov. 13, 2018, 11:20 a.m.
Publisher: plindia.com

The USFDA conducted an inspection at SUNP’s Mohali plant during 10-14 September 2018, and issued Form 483 with two observations.
Sept. 19, 2018, 11:04 a.m.
Publisher: motilaloswal.com

Sun Pharmaceutical Industries (SPIL) has received the US Food and Drug Administration or USFDA’s approval for Xelpros - a novel drug formulation of Xalatan (latanoprost) - the most widely prescribed treatment for Glaucoma.
Sept. 17, 2018, 11:29 a.m.
Publisher: nirmalbang.com

US FDA recently conducted an inspection at SUNP’s Halol plant from 27-31 August and issued Form-483 with six observations.
Sept. 7, 2018, 10:38 a.m.
Publisher: motilaloswal.com

SUNP’s sales, adj. EBITDA and adj. PAT grew by 6%, 7% and 1% QoQ respectively due to strong growth in India formulations and US generics as those contributes 66% of consolidated sales.
Aug. 16, 2018, 10:01 a.m.
Publisher: plindia.com

Net Revenues for the quarter increased by 16.3% YoY to Rs 72.2 bn, above our expectation of Rs 66.4 bn.
Aug. 16, 2018, 9:49 a.m.

-->